Latest Vidaza Stories
SAN DIEGO, June 17, 2014 /PRNewswire/ -- Mirati Therapeutics, Inc.
Study Meets Pre-Specified CR/CRi Rate in First Nine Patients SAN DIEGO, June 10, 2014 /PRNewswire/ -- MEI Pharma, Inc.
Data from Three Ongoing Phase II Trials of Pracinostat Anticipated by Year End SAN DIEGO, Jan. 14, 2014 /PRNewswire/ -- MEI Pharma, Inc.
WALTHAM, Mass., April 26 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Celgene's Vidaza (azacitidine) (seven-day dosing) will retain Decision Resources' proprietary clinical gold standard status through 2013 for the treatment of high-risk myelodysplastic syndromes.
The Need for More-Efficacious Treatments Creates Significant Opportunity for Drug Developers in this Niche Market, According to a New Report from Decision Resources WALTHAM, Mass., May 5 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, through 2012, growth in the myelodysplastic syndromes drug market will be driven principally by the launch in Europe of Celgene's Vidaza and Revlimid.
VIDAZA Restores Gene Function to Double Survival and Increase Transfusion Independence CROSSWICKS, N.J., Feb.
A French-led international study suggests acute myeloid leukemia patients treated with Vidaza (azacitidine) have significantly increased overall survival. Acute myeloid leukemia is a cancer in which abnormal cells accumulate in bone marrow and interfere with normal blood cell production.
Randomized Comparator Study to Evaluate Efficacy of Commercially Available Hypomethylating Agents WOODCLIFF LAKE, N.J., Dec.
The Aplastic Anemia & MDS International has announced that the European Committee for Medicinal Products for Human Use has awarded Vidaza a positive opinion for the treatment of myelodysplastic syndromes patients who are not eligible for stem cell transplants.
- Stoppage; cessation (of labor).
- A standing still or idling (of mills, factories, etc.).